Literature DB >> 31849723

The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective.

Laura Orsolini1,2,3, Stefania Chiappini1, Duccio Papanti1, Domenico De Berardis3,4,5, John M Corkery1, Fabrizio Schifano1.   

Abstract

The critical spread and dissemination of novel psychoactive substances (NPS), particularly among the most vulnerable youngsters, may pose a further concern about the psychotic trajectories related to the intake of new synthetic drugs. The psychopathological pattern of the "new psychoses" appears to be extremely different from the classical presentation. Therefore, clinicians need more data on these new synthetic psychoses and recommendations on how to manage them. The present mini-review aims at deepening both the clinical, psychopathological features of synthetic/chemical NPS-induced psychoses and their therapeutic strategies, according to the different NPS classes implicated, by underlining the main differences with the "classical" psychoses. A comprehensive review was conducted using the PubMed/Medline database by combining the search strategy of free-text terms and exploding a range of MESH headings relating to the topics of novel psychoactive substances and synthetic/chemical psychoses as follows: {(Novel Psychoactive Substances[Title/Abstract]) AND Psychosis[Title/Abstract])} and for each NPS categories as well, focusing on synthetic cannabinoids and cathinones, without time and/or language restrictions. Finally, an overview of the main clinical and psychopathological features between classical versus NPS-induced chemical/synthetic psychoses is provided for clinicians working with dual disorders and addiction psychiatry. Further insight is given here on therapeutic strategies and practical guidelines for managing patients affected with synthetic/chemical NPS-induced psychoses.
Copyright © 2019 Orsolini, Chiappini, Papanti, De Berardis, Corkery and Schifano.

Entities:  

Keywords:  NPS; chemical psychosis; novel psychoactive substances; psychosis; synthetic psychosis

Year:  2019        PMID: 31849723      PMCID: PMC6896660          DOI: 10.3389/fpsyt.2019.00851

Source DB:  PubMed          Journal:  Front Psychiatry        ISSN: 1664-0640            Impact factor:   4.157


  115 in total

1.  Synthetic cannabinoid exposures reported to Texas poison centers.

Authors:  Mathias B Forrester; Kurt Kleinschmidt; Evan Schwarz; Amy Young
Journal:  J Addict Dis       Date:  2011-10

Review 2.  3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online.

Authors:  M Coppola; R Mondola
Journal:  Toxicol Lett       Date:  2011-10-08       Impact factor: 4.372

3.  Smoking synthetic marijuana leads to self-mutilation requiring bilateral amputations.

Authors:  Karim A Meijer; Russell R Russo; Dhaval V Adhvaryu
Journal:  Orthopedics       Date:  2014-04       Impact factor: 1.390

4.  Spice: a legal marijuana equivalent.

Authors:  Lucas A Johnson; Rebecca L Johnson; Chris Alfonzo
Journal:  Mil Med       Date:  2011-06       Impact factor: 1.437

5.  Detection of JWH-018 metabolites in smoking mixture post-administration urine.

Authors:  Tim Sobolevsky; Ilya Prasolov; Grigory Rodchenkov
Journal:  Forensic Sci Int       Date:  2010-04-28       Impact factor: 2.395

6.  Could spice drugs induce psychosis with abnormal movements similar to catatonia?

Authors:  Gonzalo Haro; Carmen Ripoll; María Ibáñez; Teresa Orengo; Víctor M Liaño; Emilio Meneu; Félix Hernández; Francisco Traver
Journal:  Psychiatry       Date:  2014       Impact factor: 2.458

7.  Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.

Authors:  Stella Welter; Caroline Lücke; Alexandra Philomena Lam; Christina Custal; Sebastian Moeller; Peter Sörös; Christiane M Thiel; Alexandra Philipsen; Helge H O Müller
Journal:  Eur Addict Res       Date:  2017-08-25       Impact factor: 3.015

8.  Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.

Authors:  Maren Hermanns-Clausen; Stefan Kneisel; Bela Szabo; Volker Auwärter
Journal:  Addiction       Date:  2012-11-01       Impact factor: 6.526

9.  Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.

Authors:  Jennifer Waugh; Javad Najafi; Leonard Hawkins; Simon L Hill; Michael Eddleston; J Allister Vale; John P Thompson; Simon H L Thomas
Journal:  Clin Toxicol (Phila)       Date:  2016-04-19       Impact factor: 4.467

10.  Severe Psychosis, Drug Dependence, and Hepatitis C Related to Slamming Mephedrone.

Authors:  Helen Dolengevich-Segal; Beatriz Rodríguez-Salgado; Jorge Gómez-Arnau; Daniel Sánchez-Mateos
Journal:  Case Rep Psychiatry       Date:  2016-05-10
View more
  1 in total

1.  Duration of Untreated Disorder and Cannabis Use: An Observational Study on a Cohort of Young Italian Patients Experiencing Psychotic Experiences and Dissociative Symptoms.

Authors:  Valerio Ricci; Giovanni Martinotti; Franca Ceci; Stefania Chiappini; Francesco Di Carlo; Julius Burkauskas; Ottavia Susini; Debora Luciani; Diego Quattrone; Domenico De Berardis; Mauro Pettorruso; Giuseppe Maina; Massimo Di Giannantonio
Journal:  Int J Environ Res Public Health       Date:  2021-11-30       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.